Corient Private Wealth
ADMA icon

Corient Private Wealth’s ADMA Biologics ADMA Stock Holding History

Corient Private Wealth’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Buy
317,861
+254,124
+399% +$2.32M ﹤0.01% 1204
2026
Q1 		$574K Sell
63,737
-27,630
-30% -$436K ﹤0.01% 1956
2025
Q4 		$1.67M Buy
91,367
+33,541
+58% +$565K ﹤0.01% 1240
2025
Q3 		$848K Sell
57,826
-19,590
-25% -$336K ﹤0.01% 1511
2025
Q2 		$1.41M Buy
77,416
+41,260
+114% +$841K ﹤0.01% 1198
2025
Q1 		$717K Buy
36,156
+564
+2% +$9.75K ﹤0.01% 1429
2024
Q4 		$610K Sell
35,592
-1,038
-3% -$19.5K ﹤0.01% 1513
2024
Q3 		$732K Buy
36,630
+4,291
+13% +$66.7K ﹤0.01% 1553
2024
Q2 		$362K Buy
32,339
+1,540
+5% +$12.9K ﹤0.01% 1808
2024
Q1 		$203K Buy
30,799
+13
+0% +$71 ﹤0.01% 2095
2023
Q4 		$139K Hold
30,786
– – ﹤0.01% 2120
2023
Q3 		$110K Hold
30,786
– – ﹤0.01% 2012
2023
Q2 		$114K Buy
30,786
+13,293
+76% +$49.3K ﹤0.01% 1964
2023
Q1 		$57.9K Hold
17,493
– – ﹤0.01% 1928
2022
Q4 		$67.9K Buy
+17,493
New +$54K ﹤0.01% 1604

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Corient Private Wealth's ADMA Position: Q2 2026 in Review

Corient Private Wealth increased its ADMA Biologics (ADMA) stake by 399% in Q2 2026, buying an estimated $2.32M and bringing the position to 317,861 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

Corient Private Wealth first reported a position in ADMA in Q4 2022 and has held it in 15 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Corient Private Wealth held 317,861 shares of ADMA Biologics worth $2.66M as of Q2 2026.
  • Corient Private Wealth bought 254,124 ADMA Biologics shares in Q2 2026, an estimated $2.32M.
  • ADMA Biologics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1204 holding.
  • Corient Private Wealth first reported a position in ADMA Biologics in Q4 2022 and has held it in 15 quarters since.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.